Huntington’s Disease


To inquire about your eligibility to enroll in one of our clinical trials, please email or call our clinic’s front office at 713-486-0500 and ask to speak to a research coordinator.

Collaborative Studies with Pharmaceutical Companies

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease (KINECT-HD)
The purpose of this study is to evaluate the effectiveness of valbenazine to reduce chorea associated with Huntington’s Disease

  • Patients with chorea associated with Huntington’s Disease
  • Sponsored by Neurocrine Biosciences Inc.
  • Age: 18-75 years
  • Study will last for approximately 18 weeks

Principal Investigator: Dr. David Hunter